Document is current
Any future updates will be listed below
-
Authors
Xiao, Tuo
Chen, Yuhao
Jiang, Bo
Huang, Mengjie
Liang, Yanjun
Xu, Yue
Zheng, Xumin
Wang, Wenjuan
Chen, Xiangmei
Cai, Guangyan https://orcid.org/0000-0001-8586-6353
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82170686)
Chinese People’s Liberation Army (22KJLJ001)
- License Information
-
More Information
Article History
Received: 8 September 2024
Accepted: 10 January 2025
First Online: 28 February 2025
Declarations
:
: Human umbilical cord blood MSCs used in this study were donated by Wuhan Optic Valley Zhongyuan Pharmaceutical Co. Ltd, which had confirmed that there was initial ethical approval for collection of human cells, and that informed consent was duly signed by the donors. The animal experiments were conducted in line with the ARRIVE guidelines 2.0. All the animal experimental procedures and therapeutic experiment involving MSCs were reviewed and approved by the Institutional Animal Care and Use Committee of the Chinese People’s Liberation Army General Hospital. (Project title: Clinical study of stem cell therapy for severe acute kidney injury; Ethics lot number: 2022-X18-22; Date of approval: March 18, 2022).
: Not applicable.
: The authors have no conflicting interests.
